Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Childhood Absence Epilepsy: later-stage trial registry
1 of 4 indexed Childhood Absence Epilepsy trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Childhood Absence Epilepsy: 4 US clinical trials tracked, 1 recruiting.
Childhood Absence Epilepsy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Biopharma SRL, running 2 of these trials.
Enrollment posture brief
Registry condition childhood-absence-epilepsy
OPEN 1 | RECR 25% | LATE 3 | EARLY 0 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Childhood Absence Epilepsy lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Childhood Absence Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Childhood Absence Epilepsy is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL
NCT06315322
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL
NCT04666610
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
Children's Hospital Medical Center, Cincinnati
NCT00088452
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study
Icahn School of Medicine at Mount Sinai
NCT00041951
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Childhood Absence Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Childhood Absence Epilepsy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Childhood Absence Epilepsy page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Childhood Absence Epilepsy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UCB Biopharma SRL sponsors the most Childhood Absence Epilepsy trials on record, review their full trial history before evaluating a specific study. See UCB Biopharma SRL's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Childhood Absence Epilepsy condition card totals 4 registered trials; most-linked intervention Valproic acid; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.